Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer

1 Sept 2022

Abstract excerpt

Ivermectin is a widely used antiparasitic drug and shows promising anticancer activity in various cancer types. Although multiple signaling pathways modulated by ivermectin have been identified in tumor cells, few studies have focused on the exact target of ivermectin. Herein, we report the pharmacological effects and targets of ivermectin in prostate cancer. Ivermectin caused G0/G1 cell cycle arrest, induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Parasitic Diseases Research and Treatment
Share to Sex and Gender in Healthcare

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36050295
DOI: 10.1038/s41419-022-05182-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancerPMID 36050295Read ↗

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor modelsSemantic proximity Read ↗

Investigation of the Effects of Galectin-1 on Enzalutamide Sensitivity and Cellular Functions in Prostate Cancer Cells and Its Clinical Diagnostic ValueSemantic proximity Read ↗

Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity Read ↗

Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatmentSemantic proximity Read ↗

Flightless I Homolog Reverses Neo-Endocrine Therapy Resistance through YBX1/PD-L1 Axis Mediated-Immune Evasion in Prostate CancerSemantic proximity Read ↗

FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expressionSemantic proximity Read ↗

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read ↗

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancerSemantic proximity Read ↗

Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway.Semantic proximity Read ↗

Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapySemantic proximity Read ↗

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and AndrogenSemantic proximity Read ↗

Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3’, 5’-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.